High albumin levels can be indicative of higher expression levels of the neonatal Fc receptors (FcRn), which offer both albumin and immunoglobulins a protective mechanism against lysosomal catabolism by recycling them across the plasma membrane back to the circulatory system [32, 43]. clinical remission at week 26 Bioanalysis Plasma risankizumab concentrations were Garcinone C determined using a validated, enzyme-linked immunosorbent assay method performed at PPD Development LLC (Richmond, VA, USA). The assay detects free risankizumab using a polyclonal anti-risankizumab antibody as a capture reagent and a biotinylated anti-risankizumab idiotype antibody as the detection reagent. The method is applicable for the quantitation of risankizumab within a nominal range of 5C100?ng/mL, with a lower limit of quantification of 5?ng/mL. Plasma samples above the upper limit of quantitation were diluted and re-assayed. Across studies, overall precision was high (% coefficient of variation was?Garcinone C the ADA titer. The samples from Studies 2 and 3 were also further characterized in a validated, cell-based neutralizing anti-drug antibody (NAb) assay (via assessment of IL-23-induced STAT3 phosphorylation), followed by a specificity assay (using a mAb against risankizumab as a positive control). The NAb assay was not conducted for Study 1. Population-Pharmacokinetic Analyses Software, and Model Selection Criteria The pharmacokinetic model was developed using a non-linear mixed-effects modeling approach with NONMEM software (version 7.4.1; ICON Development Solutions, Ellicott City, MD, USA) [29]. Model parameters were estimated using the first-order conditional estimation method with interaction between inter-individual variability (IIV) and residual variability (FOCE with interaction). The objective function value (OFV), a goodness-of-fit statistic, Garcinone C Garcinone C was used to compare the fits of nested models, where the difference in the OFV (OFV) for models being compared can serve as a likelihood ratio test approximately following a chi-squared distribution. A parsimonious approach was used for model development, and the model with the least number of parameters that could adequately describe the data was selected. With the exception of the backward elimination process in the covariate search where was set to 0.001, was set to 0.01 for all other steps. Perl Speaks NONMEM (version 4.6.0) [30] and R (version 3.4.0) [31] were used to assist with developing and evaluating the model. Model Development Based on visual examination of the data, a two-compartment model with a linear elimination process was selected as the starting model. The model (using the ADVAN4 subroutine in NONMEM) was parameterized in terms of clearance (is the estimate for the is the typical population estimate of the is the parameter for individual deviation from was assumed to be normally distributed with a mean of 0 and a variance of (0, is the observed risankizumab plasma Garcinone C concentration of the is the corresponding model-predicted risankizumab concentration, and and represent the proportional and additive residual random errors, respectively. These residual random errors were assumed to be independently normally distributed with a mean of 0 and a variance of (0, represents 1 (proportional) or 2 (additive) model structures in the combined error model. Once the base model was developed, the well-established influence of body weight on the disposition of mAbs [32] was introduced into the model parameters (as an example is depicted in Eq. (3): for a reference 70-kg individual, is the body weight (kg), and and is the number of continuous covariates, is the is the median value for the is the exponent estimate for the power model Rabbit Polyclonal to CDX2 characterizing the effect of the is the number of categorical covariates and is the proportional difference estimate for the effect of the takes a value of 0.
Categories